Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: A phase I study

British Journal of Cancer

Volumn 92, Issue 5, 2005, Pages 815-819

  Maraveyas, A ^a,b   Sgouros, J ^a   Upadhyay, S ^b   Abdel Hamid, A H ^b   Holmes, M ^b   Lind, M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

Brain metastases; Gemcitabine; Phase I study; Radiosensitisation

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG FATALITY; DRUG POTENCY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; KIDNEY CARCINOMA; LETHAL DOSE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; SEPSIS; THROMBOCYTOPENIA;

ADULT; AGED; BRAIN NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; REMISSION INDUCTION;

EID: 16244381701     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602444     Document Type: Article

References (23)

1. Blackstock AW, Bernard SA, Richards F (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212
2. Carmichael J (1998) The role of gemcitabine in the treatment of other tumours. Br J Cancer 78(Suppl 3): S21-S25
3. Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F (2003) Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98: 337-343
4. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha BD, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS (2001) Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I study and intracellular drug incorporation study. J Clin Oncol 19: 792-799
5. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Psych Res 12: 189-198
6. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, Creazzola S, Gatani T, Fiore F, Guida C, Scognamiglio F (1999) Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 19: 4535-4538
7. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R (1991) A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20: 53-58
8. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43: 795-803
9. Lawrence T, Blackstock W, McGinn C (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13: 13-21
10. Lawrence TS, Davis MA, Hough A, Rehemtulla A (2001) The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 7: 314-319
11. Lawrence TS, Eisbruch A, Shewach DS (1997) Gemcitabine-mediated radiosensitization. Semin Oncol 24(Suppl 7): S24-S28
12. Lund B, Ryberg M, Meidahl Petersen PM, Anderson H, Thatcher N, Dombernowsky P (1994) Phase II study of gemcitabine (2′, 2′difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 5: 852-885
13. Martin C, Lund B, Anderson H, Thatcher N (1996) Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 7: 351-357
14. McGinn CJ, Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11: 270-280
15. Mehta MP, Rodrigus P, Terhaard CH, Roa A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21: 2529-2536
16. Patchel R (2003) The management of brain metastases. Cancer Treat Rev 29: 533-540
17. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ (1995) Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33: 339-348
18. Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L (1992) Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs. 10: 165-170
19. Postmus PE, Haaxma-Reiche H, Smit EF, Green HJ, Karnicka H, Lewinski T, van Meerbeeck J, Clerico M, Gregor A, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G (2000) Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy-a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 18: 3400-3408
20. Robinet G, Thomas P, Breton JL, Lenna H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Perol M, Paillotin D, Mornex F (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Group Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 12: 59-67
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
22. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N (2002) Phase I trial of gemcitabine and concurrent radiotherapy in patients with inoperable non small cell lung cancer. J Clin Oncol 20: 804-810
23. Van den Bent MJ (2003) The role of chemotherapy in brain metastases. Eur J Cancer 39: 2114-2120